Payment overview · 2025
General Payments
$8,997.70
27 reported records · 11 companies
Healthcare provider profile · identity verified
Joanna Wilson, DO
Allopathic & Osteopathic Physicians|Internal Medicine · AMARILLO, TX · NPI 1942238738
Verified facts
What the public records show
CMS Open Payments records show Joanna Wilson, DO received $8,997.70 in general payments during 2025 across 27 reported records.
Astellas Pharma US Inc accounted for 54.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trintellix.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $4,886.77 | 54.3% | 7 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $3,891.34 | 43.2% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.67 | 0.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.86 | 0.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.83 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.41 | 0.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.34 | 0.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.05 | 0.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.95 | 0.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.83 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.65 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,715.00 | 4 |
| Honoraria | $2,500.00 | 1 |
| Travel and Lodging | $1,112.79 | 3 |
| Food and Beverage | $669.91 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $4,886.77 | 7 | 2025 |
Source payment records
|
|||||
| ANNOVERA Normalized: annovera |
Drug | MAYNE PHARMA COMMERCIAL LLC | $3,891.34 | 8 | 2025 |
Source payment records
|
|||||
| BIJUVA Normalized: bijuva |
Drug | MAYNE PHARMA COMMERCIAL LLC | $3,891.34 | 8 | 2025 |
Source payment records
|
|||||
| NEXTSTELLIS Normalized: nextstellis |
Drug | MAYNE PHARMA COMMERCIAL LLC | $3,891.34 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.03 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 645 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 379 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 264 | 48 |
| Bupropion Xl | Bupropion Hcl | 194 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 181 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 49 |
| Gabapentin | Gabapentin | 168 | 46 |
| Montelukast Sodium | Montelukast Sodium | 168 | 46 |
| Estradiol | Estradiol | 152 | 59 |
| Buspirone Hcl | Buspirone Hcl | 137 | 31 |
| Carvedilol | Carvedilol | 137 | 32 |
| Spironolactone | Spironolactone | 137 | 35 |
| Meloxicam | Meloxicam | 134 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 132 | 36 |
| Sertraline Hcl | Sertraline Hcl | 132 | 30 |
| Losartan Potassium | Losartan Potassium | 127 | 33 |
| Pregabalin | Pregabalin | 123 | 31 |
| Tramadol Hcl | Tramadol Hcl | 118 | 32 |
| Trazodone Hcl | Trazodone Hcl | 118 | 28 |
| Ipratropium Bromide | Ipratropium Bromide | 107 | 46 |
| Mounjaro | Tirzepatide | 101 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 22 |
| Metformin Hcl | Metformin Hcl | 80 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 21 |
| Omeprazole | Omeprazole | 73 | 16 |
| Synthroid | Levothyroxine Sodium | 68 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 16 |
| Irbesartan | Irbesartan | 66 | 16 |
| Lisinopril | Lisinopril | 65 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 64 | 13 |
| Potassium Chloride | Potassium Chloride | 62 | 15 |
| Simvastatin | Simvastatin | 61 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 13 |
| Telmisartan | Telmisartan | 60 | 17 |
| Valsartan | Valsartan | 59 | 15 |
| Estradiol (Twice Weekly) | Estradiol | 57 | 15 |
| Clonazepam | Clonazepam | 55 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 11 |
| Furosemide | Furosemide | 52 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Alprazolam | Alprazolam | 49 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 46 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 13 |
| Baclofen | Baclofen | 45 | 12 |
| Ozempic | Semaglutide | 45 | 11 |
| Jardiance | Empagliflozin | 43 | 11 |
| Doxepin Hcl | Doxepin Hcl | 42 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 11 |
| Myrbetriq | Mirabegron | 42 | 12 |
| Ondansetron Odt | Ondansetron | 42 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Famotidine | Famotidine | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Nystatin | Nystatin | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 35 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 16 |
| Celecoxib | Celecoxib | 34 | 11 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Premarin | Estrogens, Conjugated | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Acyclovir | Acyclovir | 23 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Progesterone | Progesterone, Micronized | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Yuvafem | Estradiol | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Dotti | Estradiol | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Piroxicam | Piroxicam | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,997.70 · 27 records | Astellas Pharma US Inc | AIRSUPRA, ANNOVERA, BIJUVA, Cologuard Collection Kit, EVENITY, FARXIGA, KEVEYIS, Kerendia, NEXTSTELLIS, Ozempic, Rybelsus, TRINTELLIX, VOQUEZNA, Veozah, Wegovy, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error